Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma
Laure Hirsch(Harvard University), Toni K. Choueiri(Dana-Farber Cancer Institute), Ronan Flippot(Institut Gustave Roussy), Priscilla K. Brastianos(Harvard University), Bashar Abuqayas(University of Iowa), Nityam Rathi(Huntsman Cancer Institute), Philippe Barthélémy(Université de Strasbourg), Hannah Dzimitrowicz(Duke Medical Center), Amir Mortazavi(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Andreas Varkaris(Beth Israel Deaconess Medical Center), Emmanuel Seront, Subrina Farah(Dana-Farber Cancer Institute), Mehmet Asım Bilen(Emory University), Yousef Zakharia(University of Iowa Hospitals and Clinics), Katharine A. Collier(The Ohio State University), Jonathan Thouvenin(Hôpitaux Universitaires de Strasbourg), Lauren C. Harshman(Dana-Farber Cancer Institute), Rana R. McKay(University of San Diego), I. Alex Bowman(The University of Texas Southwestern Medical Center), Wenxin Xu(Dana-Farber Cancer Institute), Wanling Xie(Dana-Farber Cancer Institute), David A. Braun(Yale Cancer Center), Nieves Martínez Chanzá(Institut Jules Bordet), Laurence Albigès(Institut Gustave Roussy), Elaine T. Lam(University of Colorado Cancer Center), Neeraj Agarwal(Huntsman (United States)), Katherine M. Krajewski(Brigham and Women's Hospital), Guillermo de Velasco(Hospital Universitario 12 De Octubre), Michael R. Harrison(Duke Medical Center)
Cited by 95
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k